53 results about "Healthy subjects" patented technology

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

The invention relates to a brain anomaly network positioning method and system based on functional connection network mapping in the technical field of neural image data processing. The brain abnormal network positioning method comprises the following steps: calculating a whole brain function network diagram connected with each abnormal site by using resting state function connection data of large-scale health subjects based on a plurality of dispersed abnormal sites reported in previous literatures; then superposing the function network diagrams to obtain a network probability graph; and finally, filtering the probability graph through a threshold value to obtain a final core anomaly network graph. According to the method, the inherent functional connection architecture of the brain is used as a reference system, abnormal sites which seem to be uncorrelated in different researches are successfully traced and unified to a common and stable functional network, and compared with a single brain region marker, the generated network-level biomarker integrates more source evidences, so that the network-level biomarker has the advantages that the network-level biomarker can be widely applied to the field of biomarkers of the brain region. Therefore, the problems of result heterogeneity and inconsistency in brain abnormality discovery are solved.

The present invention relates to esters of formula (I) or pharmaceutically acceptable salts thereof and their use as medicaments, in particular for the treatment of skin diseases or skin cancer. The present invention further relates to the use of esters of formula (I) or pharmaceutically acceptable salts thereof in cosmetic and nutritional compositions for preventing or reducing the signs of aging in healthy subjects.

The present disclosure relates to an anti-fatigue Lactobacillus composition. The anti-fatigue Lactobacillus composition, which includes at least one of Lactobacillus brevis GKEX, Lactobacillus plantarum GKK1 and Lactobacillus johnsonii GKJ2 as an active ingredient, administered to a healthy subject for a continuous period of time, can significantly improve fatigue-related biochemical indices and prolong aerobic exercise time to exhaustion, and thus can be used as an active ingredient for preparation of various compositions for anti-fatigue and / or improving athletic ability.

A method of selecting a treatment for a subject having cancer is disclosed. The method comprises:(a) determining a level of catalytic activity of at least one DNA repair enzyme in a biological sample of the subject; and(b) selecting an immune checkpoint regulator as a treatment for a subject having a statistically significant different level of catalytic activity of the DNA repair enzyme as compared to the catalytic activity of the DNA repair enzyme in a biological sample of a healthy subject.

This invention relates to the field of rehabilitation training technology, and discloses a method for determining amblyopia perception training data and amblyopia perception training visual targets. The method includes: acquiring test data of the target subject, wherein the test data is data obtained from a basic amblyopia perception test of the target subject; determining the initial contrast sensitivity data of the target subject based on the test data; acquiring reference contrast sensitivity data, wherein the reference contrast sensitivity data is obtained from amblyopia perception tests of healthy subjects of the same age as the target subject; determining the target subject's weak data based on the initial contrast sensitivity data and the reference contrast sensitivity data; and determining the target subject's training data based on the weak data. This invention focuses on targeted training in weak areas, reducing ineffective training in normal areas, saving a significant amount of unnecessary training time, and improving the efficiency and targeting of amblyopia perception training.

The present application relates to the field of biological science, and particularly relates to the use of a SCN11A protein detection reagent in the preparation of a depression screening and depression treatment effect evaluation kit. It is found for the first time that the expression level of SCN11A protein in the peripheral blood serum of a depression patient is significantly higher than that of a healthy subject. The reagent for detecting SCN11A protein is used in the preparation of a depression screening kit, so that effective screening of depression and evaluation of the treatment effect of depression can be realized.

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provides an anti-succinate antibody that can serve as a cancer therapeutic agent.

A method and system enabling a determination of the risk of developing breast cancer of a subject, comprises using a magnetic resonance spectroscopy device to obtain the level of the spectral signal at 3.15 and 3.19 ppm, within the breast tissue of the subject, and comparing the level of the spectral signal obtained in the first step with a reference level of a spectral signal at 3.15 and 3.19 ppm of the breast of a healthy subject, to determine whether the level of the signal obtained in the first step exceeds the reference level of a healthy subject is comparable to that of a subject known to be at elevated risk; or is elevated to the level of persons known to be carrying a gene mutation.

The invention discloses application of FGL1 protein in preparation of a kit for diagnosing vertigo. Clinically, diagnosis of vertigo depends on diagnosis experience of doctors, complaint of patients becomes a main diagnosis basis, the doctors perform preliminary diagnosis according to physical examination, medical history inquiry and the like and then perform clear diagnosis according to etiological examination, diagnosis time is long, and preliminary diagnosis subjectivity is high. It is found that the FGL1 protein can effectively diagnose and distinguish healthy subjects and patients with vertigo, the diagnosis accuracy is high, the FGL1 protein can be used for being developed into a kit for diagnosing vertigo, and compared with an existing diagnosis method, the diagnosis efficiency and objectivity are obviously improved.

The invention belongs to the field of neurological disease diagnosis, and provides a plasma lipid marker for diagnosing Alzheimer's disease and application thereof, and the plasma lipid marker is selected from one or more of PA 16: 016: 0, PE O-18: 022: 4, PE P-16: 022: 4, TG 46: 4-FA18: 2, LPC 22: 4, ChE 22: 4, ChE 22: 0, ChE 20: 2, ChE 18: 0, ChE 16: 1 and ChE 20: 1. According to the present invention, the area under the curve (ROC) of the Alzheimer's disease subject diagnosed by the 11 plasma lipid markers is up to 1, and the Alzheimer's disease patient and the healthy subject can be accurately distinguished; detection can be completed through a venous blood collection method, a traditional cerebrospinal fluid collection method with higher trauma is replaced, and low-trauma and low-cost large-range crowd screening of the Alzheimer's disease is facilitated.

This invention provides an apparatus, method, and storage medium for assessing schizophrenic tendency based on near-infrared data. The apparatus includes a processor configured to: acquire near-infrared data of a subject; process the near-infrared data and convert the processed near-infrared data into a test image; input the test image into a classification model to obtain a classification result for the subject, wherein the classification result indicates the subject's tendency to be either healthy or schizophrenic. This invention normalizes near-infrared data based on a preset data set formed by fusing second data sequences from multiple healthy subjects and multiple schizophrenic individuals. This avoids the loss of brain activation information caused by normalization at different scales, resulting in higher accuracy when the classification model classifies the test image converted from the normalized near-infrared data.

Provided herein are computer-implemented methods of detecting cardiovascular disease in a subject. The methods include receiving an electrocardiogram (ECG) image for the subject; applying a machine-learning based algorithm to the ECG image for the subject, the algorithm being trained to distinguish a printed ECG reading of a heart with cardiovascular disease from a printed ECG reading of a healthy heart; comparing outputs of the algorithm to patterns of algorithm outputs for ECG images from healthy subjects and subjects with one or more cardiovascular diseases; and determining if the subject has cardiovascular disease based upon the outputs of the algorithm.

Pulse wave velocity (PWV) is a measure of arterial stiffness and a cardiovascular disease risk factor. Accurate PWV estimation is difficult due to complex arterial dynamics, such as longitudinal motion and natural tissue oscillations. This present disclosure relates to a robust, motion-resistant PWV estimation framework including: 1) tracking and compensating for arterial longitudinal wall motions, 2) suppressing undulating arterial motion via common mode rejection, and 3) enhancing differential signals to extract wall expansion. In vitro experiments with induced lateral motion indicate the framework's PWV estimates (6.19±0.33 m / s) closely matched reference values (6.26±0.12 m / s; error: 1.1%), outperforming methods without motion compensation (4.46±1.78 m / s; error: 28.8%). In vivo trials with five healthy subjects showed an average PWV of 4.18±0.56 m / s using the motion-resistant method, compared to 2.54±0.95 m / s without motion compensation (p<0.005). This framework enhances PWV estimation reliability, offering clinical potential for better arterial stiffness assessment and cardiovascular risk stratification.

The invention provides a kit for detecting polysaccharide ligand level and application thereof, and relates to the field of biological detection. The invention finds that the ligand level of polysaccharide compound A in serum of a patient with uterine prolapse is obviously lower than that of a healthy subject for the first time. The reagent for detecting the level of the ligand of the polysaccharide compound A is used for preparing the uterine prolapse screening kit, and effective screening of uterine prolapse can be achieved.

Aging in an individual refers to the temporal change, mostly decline, in the body's ability to meet physiological demands. Biological age (BA) is a biomarker of chronological aging, and can be used to stratify populations to predict certain age related chronic diseases. BA can be predicted from biomedical features such as brain MRI, retina or facial images, but the inherent heterogeneity in the aging process limits the usefulness of BA predicted from individual body systems. The methods disclosed herein teach a multi-modal Transformer-based architecture with cross-attention which was able to combine facial, tongue and retina images to estimate BA. The model was trained using facial, tongue and retina images from 11, 223 healthy subjects, and demonstrated that using a fusion of the three image modalities achieved the most accurate BA predictions. The approach was validated on a test population of 2,840 individuals with six chronic diseases, and obtained significant difference between chronological age (CA) and BA (AgeDiff) than that of healthy subjects. AgeDiff has the potential to be utilized as a standalonfe biomarker, or conjunctively alongside other known factors for risk stratification and progression prediction of chronic diseases. The results therefore highlight the feasibility of using multi-modal images to estimate and interrogate the aging process.

To provide a determination method or the like capable of determining a health condition of an object by using an olfactory sensor.SOLUTION: In the determination method, a computer executes processing of acquiring a response signal with respect to a target subject derived from a determination target over time detected by using an olfactory sensor including a cell having an olfactory receptor and responding to an odor molecule, and determining a health condition of the determination target based on a profile of the acquired response signal with respect to the target subject over time and a first profile obtained from a response signal with respect to a subject derived from a healthy subject and a second profile obtained from a response signal with respect to a subject derived from a non-healthy subject.SELECTED DRAWING: Figure 1

The present invention relates to the discovery of compounds of formula (I) which have the activity of modulators of the metabotropic glutamate 6 receptor (mGlu6), the modulating activity of which on the receptor can be controlled by irradiation with suitable light, thereby enabling optical control of the biological function of the receptor. The invention also relates to pharmaceutical compositions comprising said compounds of formula (I) and to the use of said compounds and pharmaceutical compositions as medicaments, in particular for the treatment and / or prophylaxis of retinitis pigmentosa, and / or for enhancing visual performance in healthy subjects.

The application belongs to the field of neurological disease diagnosis, and provides a plasma lipid marker for diagnosing Alzheimer's disease and an application thereof. The plasma lipid marker is selected from one or more of PA 16:0_16:0, PE O-18:0_22:4, PE P-16:0_22:4, TG 46:4-FA18:2, LPC 22:4, ChE 22:4, ChE 22:0, ChE 20:2, ChE 18:0, ChE 16:1, ChE 20:1. The area under the curve (ROC) of 11 plasma lipid markers for diagnosing Alzheimer's disease is as high as 1, which can accurately distinguish Alzheimer's disease patients from healthy subjects; the detection can be completed by a method of collecting venous blood, instead of a traditional method of collecting cerebrospinal fluid with higher trauma, and is helpful to realize low-trauma, low-cost mass screening of Alzheimer's disease.

Apparatus for the non-invasive in-vivo determination of changes in tissue, e.g. the myelination, of the optic nerve (ON) in a biological subject, said apparatus comprising: a laser source for generating an excitation laser beam; an optical system including a fundus camera operatively associated with the laser source for use in obtaining a fundus image for illuminating the optic nerve (ON) of a subject with the excitation laser beam; a detector (13) operatively associated with the optical system and configured to detect a Raman spectrum from the optic nerve (ON) and / or surrounding cerebral spinal fluid; and a processor provided with a computer program for comparing the detected Raman spectrum to at least one reference spectrum. The reference spectrum may correspond to the myelination of the optic nerve in a normal, healthy subject, for determining the changes in the myelination of the optic nerve of the subject based on the detecting and comparing steps from the Raman spectrum.

A technology for determining an indication of heart failure of a subject (18) is proposed. It comprises: obtaining (100a) a first signal interval (36) from a source signal recorded with an accelerometer (14) placed on the chest of a subject (18), wherein the first signal interval (36) corresponds to a first subinterval of a heart cycle: inputting (200a) the first signal interval (36) into a first autoencoder, wherein the first autoencoder is trained on the corresponding first signal intervals obtained from healthy subjects and outputs a reconstructed first signal interval (44), determining (300a) a first correlation between the first signal interval (36) and the reconstructed first signal interval (44), and determining (400) the indication of heart failure based on the first correlation.

The invention discloses the in vitro use of a non-LTR RTE biomarker, such as LINE-1, to diagnose neurodegenerative diseases, particularly tauopathies. The diagnosis is based on identifying an increase in the number of LINE-1 copies in the biological fluids of an individual, and the difference in the number of copies of a non-LTR RTE, LINE-1, per ng of DNA in a biological sample, preferably a buffy coat, between healthy subjects (Control) and ill patients. The tauopathies are: Alzheimer's Disease (EA), Mild Cognitive Impairment (DCL), Progressive Supranuclear Palsy (PSP) / Corticobasal Syndrome (SCB) and Frontotemporal Dementia (DFT). The invention also relates to a kit comprising means for detecting the biomarker in a biological sample obtained from the individual and means for comparing the levels of the biomarker of interest in the sample with a control reference obtained from healthy individuals, and relates to an in vitro method for detecting a non-LTR RTE, such as LINE-1, in a biological sample.

The invention provides a KOA rehabilitation condition monitoring method based on intestinal flora and multi-source data collaboration, and relates to the technical field of rehabilitation monitoring, the method comprises the following steps: screening KOA patients and healthy subjects, obtaining intestinal flora data, inflammatory factor data and electroencephalogram data, and obtaining electroencephalogram feature information; determining physiological state change information and rehabilitation condition information of the KOA patient in each treatment course, further determining an intervention effectiveness evaluation index, and obtaining a rehabilitation condition monitoring result. According to the method and the system, a healthy subject can be screened as a reference, and whether the physiological state of the KOA patient is changed or not and whether the KOA patient is rehabilitated or not is judged by monitoring intestinal flora, inflammatory factors and electroencephalogram data of the KOA patient, so that the rehabilitation condition of the KOA patient is accurately analyzed, and a plurality of KOA patients can be diagnosed based on the rehabilitation condition of the KOA patient. Whether the intervention treatment on the KOA patient is effective or not is determined, and an accurate data basis is provided for analysis of the intervention effect.

A method of obtaining a prognosis for a subject who has or has had leukemia who has been or is being treated with a tyrosine kinase inhibitor (TKI) is described. The method includes determining the levels of one or more of 1) total N6-methyladenosine (m6A), 2) long non-coding RNA (lncRNA) bearing m6A sites, 3) lncRNA-specific m6A, 4) the fat mass and obesity-associated gene (FTO) in a biological sample from the subject; and assigning a poor prognosis or poor TKI responder status to the subject if the level of m6A, lncRNA being m6A sites, lncRNA-specific m6A, and / or FTO is higher than the one or more corresponding control values obtained from a healthy subject. Methods of treating a subject having TKI-resistant leukemia and methods of predicting TKI resistance in a subject having leukemia are also described.

A non-invasive method for detecting bone marrow pathology is provided, comprising receiving a metacell model of multiple metacell types based on single-cell RNA sequencing (scRNA-seq) of CD34-positive cells from peripheral blood and comparing it to a control value of CD34-positive cell metacells from peripheral blood of a healthy subject. A non-invasive method for predicting the percentage of blast cells in the bone marrow and calculating an IPSS-M risk score is also provided, as well as a system for carrying out the method of the present invention.

The present invention provides methods for detecting multiple biomarkers indicative for lysosomal storage diseases from a dried blood spot. In particular, the present invention provides a method that is suited for detecting multiple biomarkers, each indicative for the presence of a distinct lysosomal storage disease in a subject, based on a single sample preparation procedure. In particular, the method allows simultaneous extraction of different biomarkers such as Lyso-Gb1 (GlcSph). Lyso-Gb3, and others from a dried blood spot sample. The invention further provides a kit of parts comprising means for conducting the methods subject of the invention. Finally, the invention provides a set of reference ranges for Lyso-Gb1 (GlcSph) and Lyso-Gb3 in healthy subjects starting from dried blot spot samples.

The invention discloses a motor imagery electroencephalogram signal classification method based on an AFFormer, and provides a novel adaptive frequency Transform model which is used for motor imagery decoding. The method comprises the following steps: firstly, adaptively decomposing an electroencephalogram into individual specific multi-band intrinsic mode functions through multivariate variational mode decomposition, and extracting features from multi-band IMFs by combining a spatial-temporal feature module; secondly, capturing global time information by adopting a Transform encoder (Transform encoder); thirdly, constructing a joint loss function to maximize the inter-class distance and minimize the intra-class distance; and individual dependency analysis is carried out on the self-acquisition data set and the open OpenBMI data set through an AFFormer. The result shows that the AFFormer is superior to a baseline algorithm under the strategies of cross validation and leave-one-out validation, the binary classification accuracy of healthy subjects under the CV strategy reaches 82.32%, and the binary classification accuracy of a patient group reaches 80.29%; the accuracy rates of the four classifications are 47.30% and 44.94% respectively, and the comparable accuracy rate of 74.41% on an OpenBMI data set is achieved.

The invention discloses a normal form for a practical small-channel dry electrode brain-computer interface (BCI) and a decoding method of the normal form for the practical small-channel dry electrode BCI. According to the method, multiple excitation forms are introduced, so that the paradigm can induce coupling of electroencephalogram signals in multiple brain regions; according to the method, a Motor Preparation (MP) normal form is designed, instructions in a video are sent out in four modes of voice and character, pure voice, pure character and arrow, a subject focuses on the voice and character instructions broadcasted in the video, and various actions such as leftward and rightward natural turning and forward left foot and right foot moving are executed according to the instructions. The MP normal form can be used as a basis for designing a closed-loop BCI system, and external equipment such as an exoskeleton and a wheelchair can be controlled by decoding a motion preparation signal of a subject. The MP normal form and the corresponding decoding method can effectively assist the rehabilitation process of a dyskinesia patient or enhance the athletic ability of a healthy subject. The method has the characteristics of noninvasiveness, convenience, low cost and low delay, and is expected to be popularized to practical application and clinical rehabilitation scenes.

Individual senescence refers to time change, mainly decline, of the ability of the body to cope with physiological needs. Biological age (BA) is a biomarker of sequential aging and can be used for demographic stratification to predict certain age-related chronic diseases. The BA may be predicted from biomedical features such as brain MRI, retina or facial images, but heterogeneity inherent in the aging process limits the usefulness of predicting the BA from the individual body system. The methods disclosed herein teach a multi-modal Transform-based architecture with cross attention that can combine face, tongue, and retinal images to estimate the BA. The model is trained using face, tongue, and retina images from 11,223 healthy subjects and demonstrates that fusion using the three image modalities achieves the most accurate BA prediction. The methods are validated on a test population including 2, 840 individuals suffering from six chronic diseases and result in a more significant difference between timing age (CA) and BA (AgeDiff) compared to healthy subjects. AgeDiff can be used as a separate biomarker or in combination with other known factors for risk stratification and progression prediction of chronic disease. Thus, these results emphasize the feasibility of using multi-modal images to estimate and explore the aging process.

The present disclosure is related, at least in part, to methods of screening subjects, such as pediatric subjects, for diseases and conditions. In some embodiments, the pediatric subjects are seemingly healthy subjects. In some embodiments, the method of assessing genetic predisposition to a set of diseases in a subject, comprises obtaining a sample from the subject, collecting genetic material from the sample, and assessing the presence or absence of at least one pathogenic variant or a likely pathogenic variant for each disease in the set of diseases described herein.